Use of allopurinol to optimize thiopurine immunomodulator efficacy in inflammatory bowel disease

Gastroenterology and Hepatology

Volumn 4, Issue 7, 2008, Pages 505-511

  Sparrow, Miles P ^a  

^a BOX HILL HOSPITAL   (Australia)

Author keywords

6 mercaptopurine; 6 methylmercaptopurine; 6 thioguanine nucleotide; Allopurinol; Azathioprine; Inflammatory bowel disease

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; 6 THIOURIC ACID; ALLOPURINOL; AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; DRUG METABOLITE; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLMERCAPTOPURINE; PREDNISOLONE; PREDNISONE; TIOGUANINE; XANTHINE OXIDASE INHIBITOR;

BONE MARROW SUPPRESSION; COLITIS; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TREATMENT FAILURE; ENTERITIS; HUMAN; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; PHARMACOGENOMICS; PRACTICE GUIDELINE; RASH; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 49149113484     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev. 2000;(2):CD000545.
2. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev. 2000;(2):CD000067.
3. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;(1):CD000478.
4. Rutgeerts P. Review article: treatment of perianal fistulizing Crohn's disease. Aliment Pharmacol Ther. 2004;(20 suppl 4):106-110.
5. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerrs P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56:1226-1231.
6. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705-713.
7. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006;130:1047-1053.
8. Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002;122:904-915.
9. Ansari A, Hassan C, Duley J, Marinaki A, Shobowale-Bakre EM, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16:1743-1750.
10. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32:651-662.
11. Roberts RL, Gearry RB, Bland MV, Sies CW, George PM, et al. Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferase gene of patients exhibiting ultra-high enzyme activity. Pharmacogenet Genomics. 2008; 18:434-438.
12. Lewis LD, Benin A, Szumlanski CL, Otterness DM, Lennard L, et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther. 1997;62:464-475.
13. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol. 1995;39:456-459.
14. Hande S, Wilson-Rich N, Bousvaros A, Zholudev A, Maurer R, et al. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis. 2006;12:251-257.
15. de Boer NK, Wong DR, Jharap B, de Graaf P, Hooymans PM, et al. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol. 2007;102:2747-2753.
16. Kennedy DT, Hayney MS, Lake KD. Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann Pharmacother. 1996;30:951-954.
17. Venkat Raman G, Sharman VL, Lee HA. Azathioprine and allopurinol: a potentially dangerous combination. J Intern Med. 1990;228:69-71.
18. Chocair P, Duley J, Simmonds HA, Cameron JS, Ianhez L, et al. Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen. Lancet. 1993;342:83-84.
19. Sparrow MP, Hande SA, Friedman S, Lim WC, Reddy SI, et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther. 2005;22:441-446.
20. Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol. 2007;5:209-214.
21. Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology. 2003;125:298-303.
22. Fox IH, Wyngaarden JB, Kelley WN. Depletion of erythrocyte phosphoribosylpyrophosphate in man. N Engl J Med. 1970;283:1177-1182.
23. Razavi M, Kraupp M, Marz R. Allopurinol transport in human erythrocytes. Biochem Pharmacol. 1993;45:893-897.
24. Borges F, Fernandes E, Roleira F. Progress towards the discovery of xanthine oxidase inhibitors. Curr Med Chem. 2002;9:195-217.
25. Olah T, Regely K, Mandi Y. The inhibitory effects of allopurinol on the production and cytotoxicity of tumor necrosis factor. Naunyn Schmiedebergs Arch Pharmacol. 1994;350:96-99.